← Tarsus Pharmaceuticals, Inc. TARS
Market Price
$69.29
Market Cap
$2.96B
P/E Ratio
N/A
Revenue (FY 2025)
↑4.9% YoY
$15.75M
3-Yr CAGR: 65.1%
Net Income
N/A
Net Margin: N/A
Free Cash Flow
↑73.6% YoY
-$22.31M
FCF Yield: -0.75%
EPS (Diluted)
N/A
Basic: N/A
Return on Equity
Efficiency
N/A
ROA: N/A
📊 Multi-Year Historical Performance & Trends
Financial Performance History
Revenue, Net Income & Free Cash Flow
Margins Trend (%)
Gross, Operating & Net Margins
Balance Sheet Strength
Cash, Debt & Equity
Cash Flow Generation
Operating Cash Flow vs CapEx vs FCF
📈 Year-over-Year (YoY) Growth History (TARS)
All monetary values in millions ($M)
⚠️ YoY Data Quality Alert
- FY 2021: Revenue YoY (-80.9%) is identical to Gross Profit YoY (-80.9%). Verify the underlying Revenue and Gross Profit values for FY 2021 and FY 2020.
| Fiscal Year | Revenue | Revenue YoY | Gross Profit | Net Income | Net Inc YoY | Diluted EPS | EPS YoY | Op. Cash Flow | Free Cash Flow | FCF YoY |
|---|---|---|---|---|---|---|---|---|---|---|
| FY 2019 | — | — | — | — | — | — | — | $-3.7M | $-3.8M | — |
| FY 2020 | $0.2M | — | $0.2M | — | — | — | — | $-21.1M | $-21.6M | -461.2% |
| FY 2021 | $0.0M | -80.9% | $0.0M | — | — | — | — | $3.7M | $3.2M | +114.6% |
| FY 2022 | $3.5M | +9,619.4% | $1.3M | — | — | — | — | $-49.0M | $-49.5M | -1,666.6% |
| FY 2023 | $10.3M | +195.4% | $7.0M | — | — | — | — | $-117.5M | $-119.0M | -140.2% |
| FY 2024 | $15.0M | +45.2% | $2.2M | — | — | — | — | $-83.0M | $-84.6M | +28.9% |
| FY 2025 | $15.7M | +4.9% | $15.7M | — | — | — | — | $-12.5M | $-22.3M | +73.6% |
Valuation
Market Price
$69.29
Market Cap
$2.96B
Enterprise Value
$2.85B
P/E Ratio
N/A
P/B Ratio
8.68
FCF Yield
-0.75%
Dividend Yield
N/A
Shares Outstanding
Profitability & Margins
Gross Margin
33.91%
Operating Margin
N/A
Net Margin
N/A
Return on Equity (ROE)
N/A
Return on Assets (ROA)
N/A
Asset Turnover
0.03x
Revenue 3-Yr CAGR
65.10%
Financial Health & Liquidity
Current Ratio
3.85
Cash Ratio
1.35
Debt / Equity
0.211
Debt / Assets
0.129
Cash & Equivalents
$183.64M
Total Debt
$72.44M
Book Value / Share
$7.98
Cash Flow Efficiency
Operating Cash Flow
-$12.45M
Capital Expenditures (CapEx)
$9.86M
Free Cash Flow
-$22.31M
OCF / Revenue
-79.07%
FCF / Revenue
-141.68%
FCF 3-Yr CAGR
N/A
Per Share Metrics
EPS (Diluted)
N/A
EPS (Basic)
N/A
Dividends / Share
N/A
Book Value / Share
$7.98
EPS YoY Growth
N/A
Balance Sheet (FY 2025)
Total Assets
$562.16M
Total Liabilities
$562.16M
Stockholders' Equity
$343.43M
Current Assets
$522.78M
Current Liabilities
$135.69M